Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

Source: 
Businesswire
snippet: 

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura., “Astellas”), by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development.